

## FDA approved drugs – June 2015

### Publication History

Received: 6 September 2015

Accepted: 17 September 2015

Published: 1 October 2015

### Citation

Vidhya V. FDA approved drugs – June 2015. *Drug Discovery*, 2015, 10(26), 250-251

## FDA APPROVED DRUGS – JUNE 2015

### 1. Drug Name: Kengreal (cangrelor)

Company: The Medicines Company

Approval Status: Approved by June 2015

Therapeutic Areas: Cardiology/Vascular Diseases

#### General Information

Kengreal is specifically indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y<sub>12</sub> platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. It is supplied as a sterile white to off-white lyophilized powder for reconstitution into an IV infusion. The recommended dosage is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI.

#### Mechanism of Action

Kengreal (cangrelor) is a direct P2Y<sub>12</sub> platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y<sub>12</sub> receptor to prevent further signalling and platelet activation.

#### Side Effects

The most common adverse effect associated with the use of Kengreal is bleeding.